Reducing amyloid plaques is a significant step forward in the fight against this debilitating disease. By doing so, we may be able to slow down or even halt the cognitive decline associated with Alzheimer’s. While the results of this early human study are indeed encouraging, further research is needed to fully understand the long-term effects and potential benefits of this groundbreaking drug. Nevertheless, this development offers hope for a future where Alzheimer’s becomes a thing of the past.
If you’re interested in learning more about this groundbreaking research and its implications for Alzheimer’s treatment, make sure to explore the underlying research mentioned in the link!
Eli Lilly and Co on Friday said early data from the first human study of its next-generation Alzheimer’s treatment showed that it lowered levels of toxic amyloid plaques in the brains of people in the earliest stages of the mind-wasting disease. The higher the dose of the…